Used in the treatment of fibrotic diseases and certain cancers, this antibody targets and neutralizes TGF-β1, a cytokine involved in tissue scarring and immune suppression. It has been investigated in clinical trials for conditions such as scleroderma, idiopathic pulmonary fibrosis, and advanced solid tumors like melanoma and renal cell carcinoma. By inhibiting TGF-β1 signaling, it helps reduce fibrosis, slow tumor progression, and enhance anti-tumor immune responses. Its application is primarily in research and therapeutic development for diseases where TGF-β pathway overactivity plays a key role.